Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sugammadex versus neostigmine for recovery after thoracoscopic-laparoscopic radical esophagectomy
ChiCTR2100054381Phase 4Not yet recruiting
- Sponsor
- Henan Cancer Hospital
- Start
- Feb 2021
- Modality
- Classical Binding Small Molecules → Small Molecules, Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, open-label trial of Sugammadex, neostigmine and atropine in esophageal cancer (3 arms), sponsored by Henan Cancer Hospital. Primary endpoints: Residual neuromuscular block conditions, Time of extraction and 1 more. Planned start Feb 2021; status: not yet recruiting.
02
Drugs
Sugammadexneostigmineatropine
03
Conditions
esophageal cancer
Beyond the preview
Go deeper on ChiCTR2100054381.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100054381.